Announcements Trials
Browse Landscape

Status

Completed 753Terminated 206Recruiting 187Active not recruiting 184Unknown 160Withdrawn 73Not yet recruiting 31Enrolling by invitation 4Suspended 3No longer available 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Expanded_access 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3

Interventions

trametinib 4nilotinib 4elotuzumab 4dabrafenib 4Amifampridine 4regorafenib 3pembrolizumab 3midostaurin 3fludarabine phosphate 3fludarabine 3Nivolumab 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Cyclophosphamide 3Crizotinib 3Bortezomib 3Axitinib 3venetoclax 2veliparib 2tazemetostat 2talimogene laherparepvec 2navitoclax 2gallium 68 PSMA-11 2ceritinib 2carbon-11 acetate 2aldesleukin 2Whole-Body Irradiation 2Trabectedin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
No longer available × Dexamethasone × Clear all
NCT02856438 2023-12-19

Early Patient Access Treatment Use Protocol CA204-220

Bristol-Myers Squibb

No longer available
Plasma cell

Multiple Myeloma

NCT02368301 2023-11-30

Expanded Access Treatment Protocol CA204-143

Bristol-Myers Squibb

No longer available
Plasma cell

Multiple Myeloma

NCT02666209 2017-08-28

Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma

Dana-Farber Cancer Institute

No longer available
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡